Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Plus Chemotherapy and Concurrent Thoracic Radiotherapy as First-line Therapy for ES-SCLC
NCT06536868Phase 2
Key facts
- Status
- Recruiting
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Countries
- 1
- Sponsor
- The Second Hospital of Shanxi Medical University
- Modality
- Monoclonal Antibodies
- Drugs
- tislelizumab
- Conditions
- small cell lung cancer (SCLC)
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in small cell lung cancer (SCLC), sponsored by The Second Hospital of Shanxi Medical University. Primary endpoint: Progression-free Survival at 2 years. Started Aug 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
ICI+EC/EP+TRT
Tislelizumab + Etoposide + Carboplatin/Cisplatin + Thoracic radiotherapy
03
Who it enrols
Patients aged 18-80 with confirmed extensive-stage small-cell lung cancer, ECOG 0-1, life expectancy >=3 months, no prior systemic therapy for extensive stage, and no prior PD-(L)1 therapy.
04
Endpoints
Primary
Progression-free Survival
Secondary
Objective Response Rate
Disease Control Rate
Overall Survival
Adverse events
Beyond the preview
Go deeper on NCT06536868.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536868.